Optibiotix chooses Biolat to distribute LPLDL in the Baltic region

The three-year licence and supply agreement introduces LPLDL to Estonia, Latvia and Lithuania

Hot on the heels of its FDA ‘generally recognised as safe’ approval, Lactobacillus plantarum (LPLDL) has signed a European distributor. ProBiotix Health, a subsidiary of Optibiotix, who produce the probiotic, have arranged an agreement with Latvian-based Biolat, to increase the products presence in the Baltic region.

The three-year licence and supply agreement introduces LPLDL to Estonia, Latvia and Lithuania, where solutions for cardiovascular illnesses are in need due to high rates of cardiovascular illnesses.

The GRAS designation allows the use of a substance in food products, as it has been deemed generally safe for consumption. As a result of this status and the new agreement, bio-active product specialists, Biolat, will have a non-exclusive licence to package and commercialise own label capsular food products featuring the probiotic strain.

Stephen O’Hara, CEO of OptiBiotix, commented: “Our agreement reflects the growing confidence in the science behind LPLDL and we believe will see the functional probiotic ingredient gain recognition on the world stage."

O’Hara added: "With cardiovascular-related deaths in the Baltic region touching on 50-60%, this distribution agreement couldn’t have come at a better time.”

Lactobacillus plantarum LPLDL is a naturally occurring bacterium which harnesses the microbiome-liver axis to impact positively upon the gut microbiome. Its ability to modulate bile acid metabolism is beneficial for heart health factors such as high blood pressure and high cholesterol.

Companies